Yale and Transcend wins US DoD grant for PTSD therapy

2023-09-22

·Pharmaceutical Technology

临床2期快速通道

Yale and Transcend wins US DoD grant for PTSD therapy

Preview

来源: Pharmaceutical Technology

Phalguni Deswal

@Phalguni_GD

Preview

来源: Pharmaceutical Technology

Methylone (TSND-201) is a rapid-acting neuroplastogen (a biological substrate not a therapeutic). Image Credit: MargJohnsonVA / Shutterstock.

The US Department of Defense has awarded a collaborative grant to Transcend Therapeutics and Yale University (US).

The grant is to fund the preclinical research of Transcend’s lead candidate, methylone for treating post-traumatic stress disorder (PTSD). The funding builds on Yale University’s $1m Department of Defense (DoD) grant to study the mechanism of action of methylone and midomafetamine (MDMA) in PTSD.

Recommended Reports

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - Histamine Dihydrochloride in Chronic Traumatic Encephalopathy (CTE) GlobalData

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - Bavisant Dihydrochloride in Hypersomnia GlobalData

View allCompanies IntelligenceBionomics LtdYale UniversityDodTranscend Therapeutics IncView all

Methylone (TSND-201) is a rapid-acting neuroplastogen (a biological substrate not a therapeutic).

Transcend is conducting a placebo-controlled Phase I/II trial (NCT05741710) in the UK to evaluate the safety and efficacy of methylone in treating patients with severe PTSD.

Part A of the study was an open-label study and was expected to enrol up to 15 participants with PTSD. Top-line data from this part is expected by the end of this year. Part B of the trial will be a randomised, double-blind, placebo-controlled study enrolling up to 64 patients.

Transcend’s co-founder and medical adviser for the US Department of Veterans Affairs National Center for PTSD stated: “There is a tremendous demand, especially among veterans, for new and effective treatments for PTSD.”

Multiple PTSD treatments currently in development include Halucenex’s synthetic psilocybin, which showed a 40% reduction in PTSD symptoms in the Phase II trial. Bionomics is expected to announce the Phase IIb trial (NCT04951076) results for BNC210 in Q3 2023. BNC210 is a negative allosteric modulator of the α7 nicotinic acetylcholine receptor and has received a fast track designation from the Food and Drug Administration (FDA) for treating PTSD.

The US DoD has also sponsored a PTSD Phase II trial (NCT05422612) for the combination therapy of Idorsia Pharmaceuticals’ Quviviq (daridorexant), fluoxetine and vilazodone hydrochloride.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构